Brentuximab vedotin in advanced Hodgkin's lymphoma: The authors reply Correspondence

  

Authors:	Ansell, S. M.; Radford, J.; Straus, D. J.
Title:	Brentuximab vedotin in advanced Hodgkin's lymphoma: The authors reply
Keywords:	mortality; antineoplastic agent; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; hodgkin disease; tumor recurrence; lymphoma; antibody conjugate; immunoconjugates; brentuximab vedotin; humans; human
Journal Title:	New England Journal of Medicine
Volume:	387
Issue:	16
ISSN:	0028-4793
Publisher:	Massachusetts Medical Society
Date Published:	2022-10-20
Start Page:	1527
End Page:	1528
Language:	English
DOI:	10.1056/NEJMc2211125
PUBMED:	36260801
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140414954&doi=10.1056%2fNEJMc2211125&partnerID=40&md5=46c2f2366bc6585ed7ad266feb40dcbd
Notes:	Letter -- Export Date: 1 November 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/199232